SAN JOSE, Calif., Oct. 22, 2019 /PRNewswire/ -- Anixa
Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused
on harnessing the body's immune system to fight cancer, today
announced the acceptance of an abstract at the 34th
Annual Meeting of the Society for Immunotherapy of Cancer
(SITC). A poster presentation will include data from ongoing
studies utilizing Cchek™, the company's artificial intelligence
(AI) driven cancer detection technology.
The SITC meeting is being held November
6 – 10, 2019 in National Harbor, MD. Cutting-edge research
will be presented by experts in the field of applied cancer
immunotherapy and translational research. The meeting will be
attended by both U.S. and international researchers, regulators,
and healthcare professionals who are involved in cancer research
and clinical care.
Poster presentation details are as follows:
Title: Early detection of breast cancer (BCa)
through MDSC and lymphocyte immunophenotyping: from manual gating
to pattern recognition neural networks
Authors: George A. Dominguez, Ph.D.; John
Roop; Alex Polo; Anthony J. Campisi; Dmitry I. Gabrilovich, MD, Ph.D.; Amit Kumar, Ph.D.
Poster Number: P11
Location: Gaylord National Hotel &
Convention Center; Poster Hall: Prince George AB
Date and Time: Friday, November 8, 2019 (12:30
– 2:00 PM ET and 6:30 – 8:00 PM ET)
To receive a copy of the presentation, please email your request
to SITC-2019@anixa.com starting November 10,
2019 and include your name, title, and contact
information.
About Cchek™
Cchek™ is an early cancer detection
technology, which measures a patient's immunological response to a
malignancy by analyzing immune system cells in peripheral blood.
The goal is to utilize the technology to determine a
patient's cancer status from a simple blood draw, eliminating the
need for a biopsy, which can be an expensive, painful and invasive
procedure. Further, conventional methods using current cancer
screening tests often lack accuracy and reliability. Anixa's
orthogonal approach using flow cytometry coupled with artificial
intelligence provides an alternative method with greater
affordability, efficacy and efficiency. To date, Anixa has
successfully used Cchek™ to detect the presence of 20 different
cancers including lung, colon, breast and prostate. The
robust cancer detection performance of Cchek™ makes it a platform
from which multiple cancer diagnostic tests may be developed.
The first such test, a prostate cancer confirmation test, is slated
for commercial launch by the end of 2019.
About Anixa Biosciences, Inc.
Anixa is a
publicly-traded biotechnology company focused on harnessing the
body's immune system in the fight against cancer. Anixa's
therapeutic portfolio includes a cancer vaccine technology focused
on the immunization against α-Lactalbumin to prevent triple
negative breast cancer (TNBC), as well as a cancer immunotherapy
program which uses a novel type of CAR-T, known as chimeric
endocrine receptor T-cell (CER-T) technology. The company's
diagnostic portfolio consists of Cchek™, a liquid biopsy technology
for early detection of solid tumors based on the body's immune
response to the presence of a malignancy. Anixa continually
examines emerging technologies in complementary fields for further
development and commercialization. Additional information is
available at www.anixa.com.
Forward-Looking Statements: Statements
that are not historical fact may be considered forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are not
statements of historical facts, but rather reflect Anixa's current
expectations concerning future events and results. We
generally use the words "believes," "expects," "intends," "plans,"
"anticipates," "likely," "will" and similar expressions to identify
forward-looking statements. Such forward-looking statements,
including those concerning our expectations, involve risks,
uncertainties and other factors, some of which are beyond our
control, which may cause our actual results, performance or
achievements, or industry results, to be materially different from
any future results, performance, or achievements expressed or
implied by such forward-looking statements. These risks,
uncertainties and factors include, but are not limited to, those
factors set forth in "Item 1A - Risk Factors" and other sections of
our most recent Annual Report on Form 10-K as well as in our
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
We undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law. You
are cautioned not to unduly rely on such forward-looking statements
when evaluating the information presented in this press
release.
Anixa contact:
Mike Catelani
mcatelani@anixa.com
408-708-9808
Tiberend Strategic Advisors, Inc.
Sharen Tilman (Investors)
stilman@tiberend.com
646-604-5149
Johanna Bennett (Media)
jbennett@tiberend.com
212-375-2686
View original content to download
multimedia:http://www.prnewswire.com/news-releases/anixa-biosciences-announces-abstract-accepted-for-presentation-at-the-34th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc-2019-300942444.html
SOURCE Anixa Biosciences, Inc.